Armata Pharmctcl Stock Price, News & Analysis

Armata Pharmaceuticals (ARMP) reported its third quarter 2022 financial results, highlighting progress in clinical trials for its bacteriophage therapeutics. Key developments include the final enrollment phase of the SWARM-P.a. study and advancements in the AP-SA02 programs. The company recognized $1.3 million in grant revenue and expects $16.3 million in total funding from MTEC. R&D expenses rose to $8.4 million, while losses from operations increased to $(8.6) million. The company holds $25.4 million in cash as of September 30, 2022.

Armata Pharmaceuticals (ARMP) announced its Q2 2022 financial results, reporting significant advancements in bacteriophage therapeutics. The company recognized approximately $1.9 million in grant revenue and expects an additional $15 million from the Defense Health Agency. R&D expenses rose to $9 million, up from $5.2 million. Armata's operational loss increased to $9.2 million compared to $6.2 million a year prior. The company maintained a healthy cash position with $37 million in cash and equivalents. Key developments include the advancement of the AP-PA02 trial and IND approvals for the AP-SA02 program.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) has received FDA clearance for its Investigational New Drug (IND) application for AP-SA02, targeting prosthetic joint infections (PJI) caused by Staphylococcus aureus. This marks a significant advancement in Armata's phage therapy development, aimed at improving patient outcomes in antibiotic-resistant infections. The company is initiating a Phase 1b/2a trial to evaluate the safety and efficacy of AP-SA02 as an adjunct therapy. This addition expands Armata's active clinical programs focused on difficult-to-treat bacterial infections.

Armata Pharmaceuticals (NYSE American: ARMP) announced a significant milestone with the first patient dosed in its Phase 1b/2a clinical trial of AP-SA02, targeting complicated Staphylococcus aureus bacteremia. This study, developed in partnership with the US Department of Defense, aims to evaluate the safety and tolerability of AP-SA02 alongside standard antibiotics. In prior preclinical studies, AP-SA02 showed strong antimicrobial activity against 95% of evaluated S. aureus clinical isolates. The initiative is supported by a $15 million award from the DoD, emphasizing the need for innovative therapies in combating antibiotic-resistant infections.

Armata Pharmaceuticals (ARMP) announced its Q1 2022 financial results and corporate developments. The company reported approximately $1.2 million in grant revenue and plans to receive an expected $15 million in funding from MTEC. R&D expenses rose to $8 million, up from $4.4 million in Q1 2021, while general and administrative costs decreased slightly to $2 million. Loss from operations was $9 million, compared to $5.5 million in the previous year. Notably, Armata strengthened its balance sheet with a $45 million equity financing, increasing cash reserves to $46.4 million.

Innoviva reported a 5% increase in first-quarter royalties, totaling $93.5 million compared to Q1 2021. Notable earnings included $55.8 million from RELVAR®/BREO® ELLIPTA® and $29.3 million from TRELEGY® ELLIPTA®. However, income from operations saw a 2% decrease to $77.7 million due to the accounting consolidation of Entasis. Innoviva made a strategic investment of $45.0 million in Armata Pharmaceuticals and a $15.0 million offer to acquire Entasis, amidst a $9.4 million decline in asset fair values.

Armata Pharmaceuticals has successfully closed the second tranche of a $45 million private placement with Innoviva, raising approximately $26.9 million through the issuance of over 5.3 million common shares and 2.7 million warrants. This follows an initial tranche completed in February 2022 that raised $18.1 million. As of March 31, 2022, Armata has 36.1 million shares outstanding. Furthermore, their Form 10-K filed on March 17, 2022, includes a going concern note. Approximately 99% of shareholders voted in favor of the transaction, indicating strong support for the company's direction.

Armata Pharmaceuticals (ARMP) reported its fourth quarter and full year 2021 financial results, highlighting significant clinical advancements and a $45 million equity financing with Innoviva, Inc., its largest shareholder.

The company optimized its AP-PA02 cocktail to cover 90% of tested Pseudomonas aeruginosa isolates, began a Phase 2 trial for non-cystic fibrosis bronchiectasis, and advanced AP-PA03 manufacturing. Armata's cash position improved to $10.3 million, bolstered by grant revenue and ongoing partnerships.

A joint venture involving HATCHspaces, NexCore Group, and Nuveen Real Estate has acquired a 56,300 sq ft industrial facility in Playa Vista, West Los Angeles. This site will be redeveloped into a cGMP biomanufacturing facility, serving as the headquarters for Armata Pharmaceuticals (NYSE: ARMP). The facility aims to produce treatments for antibiotic-resistant infections, addressing a critical need in the life sciences sector. This acquisition marks the fifth asset for the HATCH/NexCore venture, which now controls over 500,000 sq ft of life sciences space in the region.